Roche's injectable PD-L1 inhibitor granted FDA approval for multiple cancer types - PMLiVE
Roche’s Tecentriq Hybreza, a subcutaneous PD-L1 inhibitor, approved by the FDA for multiple cancer types, offering a 7-minute injection compared to 30-60 min IV infusion. The SC formulation, combining Tecentriq with Halozyme’s Enhanze technology, is the first and only SC anti-PD-L1 immunotherapy in the US, applicable to all adult indications of IV Tecentriq. Phase 1b/3 study results showed comparable efficacy and safety profiles, with 71% of patients preferring Tecentriq Hybreza for its quicker administration and reduced clinic time.
Reference News
Roche’s Tecentriq Hybreza, a subcutaneous PD-L1 inhibitor, approved by the FDA for multiple cancer types, offering a 7-minute injection compared to 30-60 min IV infusion. The SC formulation, combining Tecentriq with Halozyme’s Enhanze technology, is the first and only SC anti-PD-L1 immunotherapy in the US, applicable to all adult indications of IV Tecentriq. Phase 1b/3 study results showed comparable efficacy and safety profiles, with 71% of patients preferring Tecentriq Hybreza for its quicker administration and reduced clinic time.